Vitamin D nuclear receptor (VDR) is expressed in a variety of tumors and can be used as a potential target for cancer treatment.189, 190, 191, 192 A potent VDR agonist (35) with the combination of 1α,25-dihydroxyvitamin D3 (1,25D) and a carborane motif was designed and synthesized by Mouriño and colleagues,193 which represented the first example of vitamin D analog binding to the LBD of VDR (Figure 6C). The gene discussed is VDR; the disease is cancer.